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T

he current CUAJ study by Nadeau and colleagues1 discusses the efficacy of double anticholinergic therapy
in children with detrusor overactivity and refractory
urinary incontinence and adds to the previous experience
by the same authors. It reiterates the safety and efficacy of
this treatment option over a longer follow-up duration of
36 months in a marginally larger cohort. The study used a
rigorous pre-inclusion and post-inclusion follow-up protocol
and it is reassuring that the beneficial effects dominated the
side effects over this follow-up duration without a significant
dropout rate or change in compliance.
It would have been valuable to know the percent of
patients who responded to anticholinergic monotherapy and
the possible predictors of requirement of double therapy
at onset as this can guide future counselling and therapy.
Can the absence of side effects on an optimized dose of
a single drug indicate the possibility of dose escalation to
achieve response or suggest poor compliance? The study
results would have been significantly more convincing if the
inclusion criteria only included patients who did not respond
to monotherapy, while showing side effects.
Continence is a binary variable and there is increasing
recognition of the need for a universal strict definition of
urinary continence to ensure adequate reporting in pediatric
studies.2 In this study, the overall “complete dryness” rate
was 41% with similar results in the neurogenic detrusor
overactivity (NDO) and non-neurogenic (DO) detrusor overactivity groups. On the other hand, the significant decrease
in the Patient Perception of Bladder Condition (PPBC) scores
suggests a better patient-reported outcome than the objective
assessment of continence. Does that indicate that perhaps, as

urologists, we are being too harsh on our reporting or is this
a reflection of patient expectations and a result of excellent
patient follow-up and counselling?
In the NDO bladder group, anticholinergic therapy plays
a dual role beyond incontinence, improving bladder compliance and reduces filling pressures. The absence of urodynamic data in the form of end-fill or detrusor leak point
pressures and compliance, combined with a 40% complete
continence rate, makes this option less appealing in this
subset of patients.
The authors deserve credit for persisting with the off-label
use of solifenacin in the pediatric population and this study
strengthens the quantity of evidence in the pediatric population. Since the authors already followed these patients fairly
systematically prior to enrollment, a crossover trial design
would have been feasible and would have subsequently
marginally enhanced the level of evidence presented.
A persistent question related to anticholinergics in pediatric patients has been the effect of these drugs on cognition, especially in the neurogenic population where baseline cognition may be impaired. The SENIOR trial, given its
limitations and the elderly age group, did not show cognitive impairment for solifenacin, but oxybutynin impaired
power and continuity of attention.3 Therefore, the effect of
long-term use of these agents in pediatric patients is still
unanswered.
The carrot and stick policy of the FDA with the Pediatric
Exclusivity provision (allows 6 additional months of market
exclusivity) and the Pediatric Research Equity Act (allows
the FDA to demand pediatric studies if the drug is likely to
be used in pediatric patients) has spurred pharmaceutical
companies to conduct more pediatric studies. This is a vital
and long-felt need expressed by pediatric practitioners who
have found it hard to extrapolate results of adult studies to
pediatric patients. Mybetriq’s (Astellas Canada Inc.) FDA
approval notice requires several deferred pediatric studies to be conducted as part of the approval requirements.
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However, the lag time before possible pediatric approval is
likely to be more than 10 years. Until then, similar off-label
pediatric studies are required and justified to bring forth
newer therapeutic options for our children.
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